Common Medications for Stable IHD¹

| Drug class / Drug | Pharmacology | Recommended dose | Contraindication Side Effect | Remarks |
|--|---|---|---|--|
| Non-steroidal Anti- inflammatory drug (NSAID) Aspirin | Acts via irreversible inhibition of platelet cyclooxygenase-1 (COX- 1) and thus thromboxane production. | 75–100mg OD | Contraindications: Hypersensitivity to NSAIDs Patients with asthma, rhinitis and nasal polyps Common side effects: Bleeding Tinnitus | Low-dose aspirin Is recommended in all stable IHD patients. (Class 1, Level A) |
| P2Y12 inhibitors Clopidogrel | Acts as antagonists of the platelet adenosine diphosphate (ADP) receptor P2Y ₁₂ , thereby inhibiting platelet aggregation. | 75mg OD | Contraindications: Active pathological bleeding (e.g. peptic ulcer, intracranial haemorrhage) Common side effects: Gastrointestinal (GI) bleeding Haemorrhage | Clopidogrel is indicated as an alternative in case of aspirin intolerance. (Class 1, Level B) |
| Short-acting nitrates Sublingual Glyceryl Trinitrate | Relax vascular smooth muscle in arteries and veins and also reduced preload, leading to reduction in myocardial oxygen demand. Onset of action: • Sublingual tablet / Translingual spray: 1– 3 min | Sublingual Glyceryl Trinitrate: 0.3–0.6mg every 5 min until the pain goes or maximum of 1.2mg within 15 min | Contraindications: • Hypertrophic obstructive cardiomyopathy Common side effects: • Headache • Flushing • Hypotension • Syncope • Reflex tachycardia | Short-acting nitrates are recommended for immediate relief of angina in patients with stable IHD. (Class 1, Level B) For 2^{nd-}line treatment, long-acting nitrates are recommended according to heart rate, blood |
| Translingual Glyceryl Trinitrate Spray | | Translingual Glyceryl Trinitrate Spray: 0.4mg (1 spray) every 5 min up to 3 doses within 15 min | | pressure and tolerance. Avoid concurrent use of phosphodiesterase-5 (PDE-5) inhibitors (e.g. sildenafil) due to risk of severe hypotension. |
| Long-acting nitrates Isosorbide Mononitrate | | Isosorbide Mononitrate: Initial: 30–60mg OM, may titrate to 120mg OM | | |

Please refer to HSG whitelist for the full list of subsidised drugs

| Drug class / Drug | Pharmacology | Recommended dose | Contraindication Side Effect | Remarks |
|----------------------------|---|--|--|---|
| Isosorbide Dinitrate | | Isosorbide Dinitrate: Initial: 5–20mg BD–TDS, may titrate to 10–40mg BD–TDS | | |
| Trimetazidine | Improve cellular tolerance to ischemia by inhibiting fatty acid metabolism and secondarily by stimulating glucose metabolism. | Immediate-release trimetazidine: 20mg TDS Modified-release trimetazidine: 35mg BD | Contraindications: Parkinson's disease Tremors and movement disorders Severe renal impairment Common side effects: Gastric discomfort Nausea Headache Movement disorders | For 2nd-line treatment, trimetazidine may be considered. (Level 2b, Class B) |
| Beta blocker Metoprolol | Acts directly on the heart to reduce heart rate, contractility, AV condition and ectopic activity. They may increase perfusion of ischaemic areas by prolonging the diastole and increasing vascular resistance in non- ischemic areas. | Immediate-release metoprolol tartrate: Initial: 50mg BD, may titrate dose up to 200mg BD Extended-release metoprolol succinate: Initial: 100mg OD, may titrate up to 400mg OD | Contraindications: • Severe bradycardia • Sick sinus syndrome • 2 nd - or 3 rd -degree heart block • Cardiogenic shock • Refractory heart failure • Asthma Common side effects: • Bradycardia • Fatigue • Depression • Bronchospasm | 1st-line therapy for relief of symptoms. (Level 1, Class A) |
| Bisoprolol | | Bisoprolol: 2.5–10mg OD | Peripheral vasoconstriction Postural | |
| Atenolol | | Atenolol: 50–100mg OD | hypotension • Impotence • Hypoglycaemia | |
| Carvedilol | | Carvedilol: Initial: 12.5mg BD, may titrate to 25mg BD | | |

| Drug class / Drug | Pharmacology | Recommended dose | Contraindication Side Effect | Remarks |
|---|---|---|--|--|
| Angiotensin converting enzyme (ACE) inhibitors Captopril Enalapril | Blocking formation of angiotensin II formation: Cause dilation of arteries and veins, thus reducing arterial pressure, preload and afterload on heart. Down regulate sympathetic | Captopril: Initial: 6.25mg TDS, may titrate up to 50mg TDS Enalapril: | Contraindications: • History of angioedema • Bilateral renal artery stenosis • Pregnancy Common side effects: • Cough | ACE inhibitors should be prescribed in all patients with Stable IHD who also have hypertension, diabetes mellitus, Left Ventricular Ejection Fraction (LVEF) 40% or less, or Chronic Kidney Disease (CKD) unless |
| | adrenergic activity. Promote renal excretion of sodium and water and thus | Initial: 2.5mg BD, may titrate to 20mg BD | Hypotension Hyperkalaemia Dizziness Headache | contraindicated. (Level 1, Class A) |
| Lisinopril | reducing blood volume, venous pressure and arterial pressure. Inhibit cardiac and vascular remodelling associated with chronic hypertension, heart failure, and myocardial infarction. | Lisinopril: Initial: 2.5–5mg OD, may titrate to 40mg OD | | |
| Perindopril | | Perindopril: Initial: 4mg OD, may titrate to 16mg OD | | |
| Angiotensin Receptor Blockers (ARB) Losartan | Blocking of angiotensin II receptors on blood vessels and other tissues. They have similar actions | Losartan: 50–100mg OD | Contraindications: • History of angioedema • Bilateral renal artery stenosis • Pregnancy | ARBs should be prescribed in all patients with Stable IHD who also have hypertension, diabetes mellitus, left ventricular systolic |
| Irbesartan | as ACE inhibitors. | Irbesartan: 150–300mg OD | Common side effects: • Hypotension • Hyperkalaemia | dysfunction, or Chronic Kidney Disease (CKD) and have indications for, but are intolerant of ACE |
| Candesartan | | Candesartan: 8–32mg OD | DizzinessHeadache | inhibitors. (Level 1, Class A) |
| Valsartan | | Valsartan: Initial: 20mg BD, may titrate to 160mg BD | | |
| Telmisartan | | Telmisartan: Initial: 40mg OD, may titrate to 80mg OD | | |

| Drug class / Drug | Pharmacology | Recommended dose | Contraindication Side Effect | Remarks |
|---|--|--|---|--|
| Non- dihydropyridine (DHP) calcium channel blocker Verapamil Diltiazem | Acts by vasodilation and reduction of the peripheral vascular resistance. | Immediate- Release verapamil: 80–160mg TDS Extended-release verapamil: 240mg OD–BD Immediate-release diltiazem: Initial: 30mg QDS, may titrate to 80mg QDS Extended-release diltiazem: Initial: 100mg OD, may titrate to 200mg OD | Contraindications: • 2 nd -or 3 rd -degree AV block • Sick sinus syndrome • Hypotension Common side effects: • Headache • Gingival hyperplasia • Constipation • Hypotension • Bradycardia | Long-acting non-DHP calcium channel blockers instead of a beta- blocker as initial therapy for relief of symptoms is reasonable. (Class 2a, Level B) Combination of non-DHP calcium channel blockers (Verapamil, Diltiazem) with beta-blockers not recommended due to risk of heart block and bradycardia. |
| Dihydropyridine calcium channel blocker Long-acting Nifedipine | | Long-acting Nifedipine: Initial: 30–60mg OD, titrate as clinically indicated up to 120mg OD Amlodipine: 5–10mg OD | Contraindications: • Severe aortic stenosis • Cardiogenic shock • Obstructive cardiomyopathy Common side effects: • Headache • Peripheral oedema • Flushing • Reflex tachycardia | Calcium channel blockers should be prescribed for relief of symptoms when beta blockers are contraindicated or cause unacceptable side effects. (Class 1, Level B) Calcium channel blockers, in combination with beta blockers, should be prescribed for relief of symptoms when initial treatment with beta blockers is unsuccessful. (Class 1, Level B) |

| Drug class / Drug | Pharmacology | Recommended dose | Contraindication Side Effect | Remarks |
|--------------------------------|---|---|--|--|
| Statins Atorvastatin | Acts by competitively inhibiting HMG-CoA reductase, the enzyme that catalyses the rate- limiting step in cholesterol biosynthesis. | Atorvastatin: Moderate- intensity: 10–20mg High-intensity: 40–80mg | Contraindications: • Active liver disease • Unexplained persistent elevation of serum transaminases • Pregnancy • Breastfeeding | In addition to therapeutic lifestyle changes, a moderate or high dose of a statin therapy should be prescribed, in the absence of contraindications or |
| Lovastatin | inhibitors also possess pleiotropic properties including improved endothelial function, | Lovastatin: Moderate- intensity: 40mg | Breastreeding Common side effects: Myalgia Headache | documented adverse effects. (Class 1, Level B) For patients with |
| Rosuvastatin | reduced inflammation at the site of the coronary plaque, inhibition of platelet aggregation and anticoagulant effects. | Rosuvastatin: Moderate- intensity: 5–10mg High-intensity: 20-40mg | GI discomfort Rare side effects: Rhabdomyolysis | established IHD, high intensity statin therapy (atorvastatin or rosuvastatin) is recommended, should there be difficulty achieving the LDL |
| Simvastatin | | Simvastatin Moderate intensity: 20–40mg High-intensity: 40– 80mg | | target. |